Compare Moderna, Inc. (MRNA) vs Old National Bancorp Common Stock (ONB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Moderna, Inc. vs Old National Bancorp Common Stock — how do they compare? Moderna, Inc. trades at $222.7 (market cap $90.35B), while Old National Bancorp Common Stock trades at $24.48 (market cap $9.38B). The key difference: Moderna, Inc. is far larger — about 9.6× Old National Bancorp Common Stock's market cap, and Old National Bancorp Common Stock pays a 2.37% dividend while Moderna, Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold Moderna, Inc. for 59 Days and Old National Bancorp Common Stock for 0 Days on average.
| MRNA | ONB | |
|---|---|---|
Market Cap | $90.35B | $9.38B |
Volume | 16,579,584 | 5,364,685 |
Sector | Health | Financials |
52-Week High | $226.30 | $27.29 |
52-Week Low | $22.36 | $19.60 |
Typical Hold Time | 59 Days | 0 Days |
Enterprise Value | $86.50B | $16.03B |
Dividend Yield | — | 2.37% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Moderna (MRNA) trades at $216.25, up 1.17% with a bullish technical signal as it joins the Nasdaq-100 index. Despite beating Q2 2026 EPS estimates, the company faces fundamental challenges with negative net income margins (-142.58%) and declining revenue from $18.9B in 2022 to $1.92B in 2025. The stock has rallied over 500% in 2026, creating valuation concerns with a P/S ratio of 40.29.
While Nasdaq inclusion and cancer vaccine pipeline progress offer upside potential, Moderna's high valuation and persistent losses present significant risk. Analyst consensus is mixed with a $115.70 price target below current levels, indicating cautious sentiment despite recent momentum. Investors face tension between growth prospects and financial sustainability.
ONB trades at $24.62, down 0.73% on the day, with a neutral technical outlook and key support at $24. The company shows strong fundamentals, with a P/E of 10.89 and net income margin of 31.39%, and has beaten earnings estimates for three consecutive quarters. Recent news highlights upcoming Q3 earnings and positive institutional investment activity.
The outlook for ONB is positive, supported by robust earnings growth and a 'Buy' consensus from analysts with a $29.67 price target. Key risks include potential earnings volatility and macroeconomic pressures on the banking sector. Upside potential exists if the company continues its trend of exceeding earnings expectations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Moderna, Inc.
Moderna, Inc. operates as a clinical stage biotechnology company. The Company focuses on the discovery and development of messenger RNA (mRNA) therapeutics and vaccines. Moderna develops mRNA medicines for infectious, immuno-oncology, and cardiovascular diseases.
Read more on MRNA →About Old National Bancorp Common Stock
Old National Bancorp is the bank holding company for Old National Bank, providing consumer banking, commercial banking, wealth management, and capital markets services across Indiana, Kentucky, Michigan, Minnesota, and Wisconsin.
Read more on ONB →
